A Phase 3 interventional study of Rivaroxaban (Xarelto, BAY59-7939) and Rivaroxaban (Xarelto, BAY59-7939) in Prevention & Control, sponsored by Bayer. Completed at 565 sites in 33 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-11-28.
Sponsored by Bayer · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing rivaroxaban in Coronary Artery Disease — 3 open to participants now, 3 under way, none of them phase 3. Rivaroxaban · Coronary Artery Disease.
Among the 14 studies testing rivaroxaban in Coronary Artery Disease, this one has the largest enrollment, is one of 2 that started in 2013, is one of 3 in phase 3, and was the 2nd registered.
4,863 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.
Browse Coronary Artery Disease studies →3 of the 14 studies testing rivaroxaban in Coronary Artery Disease are open now, in 2 countries. Recruiting first, the newest first:
China National Center for Cardiovascular Diseases · Sites in China
Ages 18–75
Seoul National University Bundang Hospital · Sites in Korea, Republic of
Ages 19+
J.P.S Henriques
Ages 18+
By country, each count listing its studies:
Rivaroxaban: first FDA approval 2011 (XARELTO), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 588 Coronary Artery Disease studies recruiting now, 402 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 38 take children under 18; 48 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 2 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 27,395 is above the median of 124 across 3,010 interventional studies indexed under Coronary Artery Disease.
Median enrollment 104 across the 14 interventional studies. Of the 8 that completed or were terminated, 5 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 14 have an industry lead sponsor. The 10 most frequent:
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
14 studies in Coronary Artery Disease by Bayer: 1 open now, 1 under way, none of them phase 3. Of 12 finished, 3 (25%) have results posted.
Among the 14 studies in Coronary Artery Disease by Bayer, this one is one of 3 that started in 2013, is one of 3 in phase 3, and was the 3rd registered.
Bayer’s Coronary Artery Disease studies by the year they started, since 2011.
2 of the studies testing rivaroxaban in Coronary Artery Disease that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05638867China National Center for Cardiovascular DiseasesNOAC Therapy Guided by PARIS Risk Score and D-dimer in Patients With ACS After PCI | 2026-12 |
| NCT07796217Seoul National University Bundang HospitalComparison of Clopidogrel-based Antiplatelet Agent Treatment and Aspirin Plus Low Dose Rivaroxaban Therapy | 2027-06-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 14 studies testing rivaroxaban in Coronary Artery Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Bayer’s 14 in Coronary Artery Disease:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objectives of this study are:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects with CAD must also meet at least one of the following criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received rivaroxaban 2.5 mg twice daily (bid) and aspirin 100 mg once daily (od). All doses were provided in tablet form for oral administration. Participants who did not have a continuous need to take a proton pump inhibitor (PPI), were additionally randomized 1:1 to receive pantoprazole 40 mg (tablet form for oral administration, od) or matching placebo od. Participants who consented to LTOLE part received open label rivaroxaban 2.5 mg bid and aspirin 100 mg od in LTOLE part.
Drug: Rivaroxaban (Xarelto, BAY59-7939) · Drug: Aspirin · Drug: Pantoprazole · Drug: Pantoprazole placebo
Participants received rivaroxaban 5 mg bid and aspirin placebo od. All doses were provided in tablet form for oral administration. Participants who did not have a continuous need to take a PPI, were additionally randomized 1:1 to receive pantoprazole 40 mg (tablet form for oral administration, od) or matching placebo od. Participants who consented to LTOLE part received open label rivaroxaban 2.5 mg bid and aspirin 100 mg od in LTOLE part.
Drug: Rivaroxaban (Xarelto, BAY59-7939) · Drug: Aspirin placebo · Drug: Pantoprazole · Drug: Pantoprazole placebo
Participants received rivaroxaban placebo bid and aspirin 100 mg od. All doses were provided in tablet form for oral administration. Participants who did not have a continuous need to take a PPI, were randomized 1:1 to receive pantoprazole 40 mg (tablet form for oral administration, od) or matching placebo od. Participants who consented to LTOLE part received open label rivaroxaban 2.5 mg bid and aspirin 100 mg od in LTOLE part.
Drug: Aspirin · Drug: Rivaroxaban placebo · Drug: Pantoprazole · Drug: Pantoprazole placebo
Tablet, 2.5 mg, twice daily, oral
Tablet, 5 mg, twice daily, oral
Tablet, 100 mg, once daily, oral
Aspirin matching placebo, once daily, oral
Rivaroxaban matching placebo, twice daily, oral
Tablet, 40 mg, once daily, oral, for participants who were not on a PPI and who were randomized to pantoprazole
Pantoprazole matching placebo, once daily, oral, for participants who were not on a PPI and who were randomized to pantoprazole placebo
The First Occurrence of the Composite Primary Efficacy Outcome, Myocardial Infarction (MI), Stroke, or Cardiovascular (CV) Death
Count of participants and time from randomization to the first occurrence of the composite primary efficacy outcome, MI, stroke, or CV death were evaluated. Hazard ratios were calculated and reported as statistical analysis.
Time frame: For each participant, the first occurrence of the composite primary efficacy outcome after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
The First Occurrence of the Primary Safety Outcome Major Bleeding Based on a Modification of the International Society on Thrombosis and Haemostasis (ISTH) Criteria
Modified ISTH major bleeding is defined as: i) Fatal bleeding, or ii) Symptomatic bleeding in a critical area or organ, such as intraarticular, intracranial, intramuscular with compartment syndrome, intraocular, intraspinal, liver, pancreas, pericardial, respiratory, retroperitoneal, adrenal gland or kidney; or bleeding into the surgical site requiring reoperation, or iii) Bleeding leading to hospitalization (major bleeding also includes presentation to an acute care facility with discharge on the same day). Count of participants and time from randomization to the first occurrence of the primary safety outcome major bleeding were evaluated. Hazard ratios were calculated and reported as statistical analysis.
Time frame: For each participant, the first occurrence of modified ISTH major bleeding after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
The First Occurrence of Myocardial Infarction (MI), Ischemic Stroke, Acute Limb Ischemia (ALI), or Coronary Heart Disease (CHD) Death
Count of participants and time from randomization to the first occurrence of MI, ischemic stroke, ALI, or CHD death were evaluated. Hazard ratios were calculated and reported as statistical analysis.
Time frame: For each participant, the first occurrence of MI, ALI, or CHD death after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
The First Occurrence of MI, Ischemic Stroke, ALI, or Cardiovascular (CV) Death
Count of participants and time from randomization to the first occurrence of MI, ischemic stroke, ALI, or CV death were evaluated. Hazard ratios were calculated and reported as statistical analysis.
Time frame: For each participant, the first occurrence of MI, ischemic stroke, ALI, or CV death after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
All-cause Mortality
Count of participants and time from randomization to death by all cause were evaluated. Hazard ratios were calculated and reported as statistical analysis.
Time frame: For each participants, death by any cause after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
The First Occurrence of the Composite Primary Efficacy Outcome, Myocardial Infarction (MI), Stroke, or Cardiovascular (CV) Death in LTOLE Part
Count of participants from COMPASS LTOLE initiation visit to the first occurrence of the composite primary efficacy outcome, MI, stroke, or CV death were evaluated. LTOLE: long-term open-lable extension
Time frame: For each participant, the first occurrence of the composite primary efficacy outcome after from COMPASS LTOLE initiation visit up until last LTOLE part contact date was considered. The mean time in follow-up was 428 days.
The First Occurrence of the Primary Safety Outcome Major Bleeding Based on a Modification of the International Society on Thrombosis and Haemostasis (ISTH) Criteria in LTOLE Part
Modified ISTH major bleeding is defined as: i) Fatal bleeding, or ii) Symptomatic bleeding in a critical area or organ, such as intraarticular, intracranial, intramuscular with compartment syndrome, intraocular, intraspinal, liver, pancreas, pericardial, respiratory, retroperitoneal, adrenal gland or kidney; or bleeding into the surgical site requiring reoperation, or iii) Bleeding leading to hospitalization (major bleeding also includes presentation to an acute care facility with discharge on the same day). Count of participants from COMPASS LTOLE initiation visit to the first occurrence of the primary safety outcome major bleeding was evaluated. LTOLE: long-term open-lable extension
Time frame: For each participant, the first occurrence of modified ISTH major bleeding from COMPASS LTOLE initiation visit up until 2 days after the last treatment in LTOLE part was considered. The mean time in follow-up was 421 days.
All-cause Mortality in LTOLE Part
Count of participants from COMPASS LTOLE initiation visit to death by all cause were evaluated. LTOLE: long-term open-lable extension
Time frame: For each participants, death by any cause after COMPASS LTOLE initiation visit up until the the last LTOLE part contact date was considered. The mean time in follow-up until that date was 428 days.
Study was conducted at 608 centers with randomized participants in 33 countries between 28 Feb 2013 (first patient first visit) and 15 Jun 2021 (last patient last visit of long-term open-label extension part).
| Milestone | Rivaroxaban 2.5mg + Aspirin 100mg | Rivaroxaban 5mg + Aspirin Placebo | Rivaroxaban Placebo + Aspirin 100mg |
|---|---|---|---|
| Started | 9152 | 9117 | 9126 |
| Treated with antithrombotic treatment | 9134 | 9109 | 9107 |
| Randomized to study pantoprazole/placebo | 5878 | 5859 | 5861 |
| Completed | 9132 | 9098 | 9102 |
| Not completed | 20 | 19 | 24 |
| Withdrew: Lost to follow-up | 10 | 8 | 9 |
| Withdrew: Withdrawal by subject | 10 | 11 | 15 |
| Milestone | Rivaroxaban 2.5mg + Aspirin 100mg | Rivaroxaban 5mg + Aspirin Placebo | Rivaroxaban Placebo + Aspirin 100mg |
|---|---|---|---|
| Started | 4399 | 4292 | 4273 |
| Treated in ltole part | 4379 | 4274 | 4250 |
| Completed | 4320 | 4230 | 4195 |
| Not completed | 79 | 62 | 78 |
| Withdrew: Lost to follow-up | 6 | 2 | 5 |
| Withdrew: Refused | 5 | 2 | 11 |
| Withdrew: Missing final visit | 68 | 58 | 62 |
Count of participants and time from randomization to the first occurrence of the composite primary efficacy outcome, MI, stroke, or CV death were evaluated. Hazard ratios were calculated and reported as statistical analysis.
| Participants | Rivaroxaban 2.5mg + Aspirin 100mg | Rivaroxaban 5mg + Aspirin Placebo | Rivaroxaban Placebo + Aspirin 100mg |
|---|---|---|---|
| The First Occurrence of the Composite Primary Efficacy Outcome, Myocardial Infarction (MI), Stroke, or Cardiovascular (CV) Death | 379 | 448 | 496 |
Modified ISTH major bleeding is defined as: i) Fatal bleeding, or ii) Symptomatic bleeding in a critical area or organ, such as intraarticular, intracranial, intramuscular with compartment syndrome, intraocular, intraspinal, liver, pancreas, pericardial, respiratory, retroperitoneal, adrenal gland or kidney; or bleeding into the surgical site requiring reoperation, or iii) Bleeding leading to hospitalization (major bleeding also includes presentation to an acute care facility with discharge on the same day). Count of participants and time from randomization to the first occurrence of the primary safety outcome major bleeding were evaluated. Hazard ratios were calculated and reported as statistical analysis.
| Participants | Rivaroxaban 2.5mg + Aspirin 100mg | Rivaroxaban 5mg + Aspirin Placebo | Rivaroxaban Placebo + Aspirin 100mg |
|---|---|---|---|
| The First Occurrence of the Primary Safety Outcome Major Bleeding Based on a Modification of the International Society on Thrombosis and Haemostasis (ISTH) Criteria | 288 | 255 | 170 |
Count of participants and time from randomization to the first occurrence of MI, ischemic stroke, ALI, or CHD death were evaluated. Hazard ratios were calculated and reported as statistical analysis.
| Participants | Rivaroxaban 2.5mg + Aspirin 100mg | Rivaroxaban 5mg + Aspirin Placebo | Rivaroxaban Placebo + Aspirin 100mg |
|---|---|---|---|
| The First Occurrence of Myocardial Infarction (MI), Ischemic Stroke, Acute Limb Ischemia (ALI), or Coronary Heart Disease (CHD) Death | 329 | 397 | 450 |
Count of participants and time from randomization to the first occurrence of MI, ischemic stroke, ALI, or CV death were evaluated. Hazard ratios were calculated and reported as statistical analysis.
| Participants | Rivaroxaban 2.5mg + Aspirin 100mg | Rivaroxaban 5mg + Aspirin Placebo | Rivaroxaban Placebo + Aspirin 100mg |
|---|---|---|---|
| The First Occurrence of MI, Ischemic Stroke, ALI, or Cardiovascular (CV) Death | 389 | 453 | 516 |
Count of participants and time from randomization to death by all cause were evaluated. Hazard ratios were calculated and reported as statistical analysis.
| Participants | Rivaroxaban 2.5mg + Aspirin 100mg | Rivaroxaban 5mg + Aspirin Placebo | Rivaroxaban Placebo + Aspirin 100mg |
|---|---|---|---|
| All-cause Mortality | 313 | 366 | 378 |
Count of participants from COMPASS LTOLE initiation visit to the first occurrence of the composite primary efficacy outcome, MI, stroke, or CV death were evaluated. LTOLE: long-term open-lable extension
| Participants | LTOLE Part: Rivaroxaban 2.5mg + Aspirin 100mg |
|---|---|
| The First Occurrence of the Composite Primary Efficacy Outcome, Myocardial Infarction (MI), Stroke, or Cardiovascular (CV) Death in LTOLE Part | 353 |
Modified ISTH major bleeding is defined as: i) Fatal bleeding, or ii) Symptomatic bleeding in a critical area or organ, such as intraarticular, intracranial, intramuscular with compartment syndrome, intraocular, intraspinal, liver, pancreas, pericardial, respiratory, retroperitoneal, adrenal gland or kidney; or bleeding into the surgical site requiring reoperation, or iii) Bleeding leading to hospitalization (major bleeding also includes presentation to an acute care facility with discharge on the same day). Count of participants from COMPASS LTOLE initiation visit to the first occurrence of the primary safety outcome major bleeding was evaluated. LTOLE: long-term open-lable extension
| Participants | LTOLE Part: Rivaroxaban 2.5mg + Aspirin 100mg |
|---|---|
| The First Occurrence of the Primary Safety Outcome Major Bleeding Based on a Modification of the International Society on Thrombosis and Haemostasis (ISTH) Criteria in LTOLE Part | 138 |
Count of participants from COMPASS LTOLE initiation visit to death by all cause were evaluated. LTOLE: long-term open-lable extension
| Participants | LTOLE Part: Rivaroxaban 2.5mg + Aspirin 100mg |
|---|---|
| All-cause Mortality in LTOLE Part | 282 |
Collected over Adverse events (AEs) are reported: from randomization until 2 days after the last antithrombotic study treatment or until LTOLE part initiation visit (including a mean of 478 days in between) for randomized groups (2 years on average); OR from LTOLE initiation visit up until 2 days after the last treatment for LTOLE group (421 days on average). All-Cause Mortality encompasses all death cases until the last contact (2 years on average for randomized groups; 428 days on average for LTOLE group).. Non-serious events are listed at a 0.1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rivaroxaban 2.5mg + Aspirin 100mg | 529/9,152 (5.8%) | 692/9,134 (7.6%) | 557/9,134 (6.1%) |
| Rivaroxaban 5mg + Aspirin Placebo | 566/9,117 (6.2%) | 664/9,109 (7.3%) | 529/9,109 (5.8%) |
| Rivaroxaban Placebo + Aspirin 100mg | 566/9,126 (6.2%) | 630/9,107 (6.9%) | 501/9,107 (5.5%) |
| LTOLE Rivaroxaban Rivaroxaban 2.5mg + Aspirin 100mg | 283/12,964 (2.2%) | 292/12,903 (2.3%) | 49/12,903 (0.4%) |
| Event | Rivaroxaban 2.5mg + Aspirin 100mg | Rivaroxaban 5mg + Aspirin Placebo | Rivaroxaban Placebo + Aspirin 100mg | LTOLE Rivaroxaban Rivaroxaban 2.5mg + Aspirin 100mg |
|---|---|---|---|---|
| Acute kidney injuryRenal and urinary disorders | 29/9134 | 22/9109 | 20/9107 | 8/12903 |
| PneumoniaInfections and infestations | 15/9134 | 21/9109 | 22/9107 | 17/12903 |
| SepsisInfections and infestations | 18/9134 | 18/9109 | 17/9107 | 6/12903 |
| CataractEye disorders | 17/9134 | 11/9109 | 7/9107 | 0/12903 |
| Urinary tract infectionInfections and infestations | 17/9134 | 14/9109 | 9/9107 | 7/12903 |
| Lung neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 17/9134 | 14/9109 | 11/9107 | 8/12903 |
| Large intestine polypGastrointestinal disorders | 8/9134 | 14/9109 | 9/9107 | 1/12903 |
| Chest painGeneral disorders | 9/9134 | 14/9109 | 5/9107 | 2/12903 |
| AnaemiaBlood and lymphatic system disorders | 13/9134 | 10/9109 | 2/9107 | 5/12903 |
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 13/9134 | 10/9109 | 4/9107 | 4/12903 |
| Event | Rivaroxaban 2.5mg + Aspirin 100mg | Rivaroxaban 5mg + Aspirin Placebo | Rivaroxaban Placebo + Aspirin 100mg | LTOLE Rivaroxaban Rivaroxaban 2.5mg + Aspirin 100mg |
|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 188/9134 | 181/9109 | 195/9107 | 0/12903 |
| DiarrhoeaGastrointestinal disorders | 48/9134 | 58/9109 | 26/9107 | 5/12903 |
| Haemorrhage subcutaneousSkin and subcutaneous tissue disorders | 49/9134 | 18/9109 | 17/9107 | 0/12903 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 38/9134 | 29/9109 | 24/9107 | 1/12903 |
| Back painMusculoskeletal and connective tissue disorders | 25/9134 | 37/9109 | 25/9107 | 0/12903 |
| ContusionInjury, poisoning and procedural complications | 37/9134 | 22/9109 | 27/9107 | 2/12903 |
| DizzinessNervous system disorders | 25/9134 | 25/9109 | 35/9107 | 2/12903 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 28/9134 | 26/9109 | 30/9107 | 0/12903 |
| Diabetes mellitusMetabolism and nutrition disorders | 26/9134 | 16/9109 | 28/9107 | 0/12903 |
| Abdominal pain upperGastrointestinal disorders | 28/9134 | 18/9109 | 21/9107 | 5/12903 |
Intent-to-treat analysis set (ITT): included all participants randomized to antithrombotic treatment for the initial study part. The ITT set comprised both participants randomized to pantoprazole/placebo and participants not randomized to pantoprazole/placebo.
| Age, Continuous(Years) | Rivaroxaban 2.5mg + Aspirin 100mg | Rivaroxaban 5mg + Aspirin Placebo | Rivaroxaban Placebo + Aspirin 100mg | Total |
|---|---|---|---|---|
| Mean | 68.3 ± 7.9 | 68.2 ± 7.9 | 68.2 ± 8.0 | 68.2 ± 7.9 |
| Sex: Female, Male(Participants) | Rivaroxaban 2.5mg + Aspirin 100mg | Rivaroxaban 5mg + Aspirin Placebo | Rivaroxaban Placebo + Aspirin 100mg | Total |
|---|---|---|---|---|
| Female | 2059 | 1972 | 1989 | 6020 |
| Male | 7093 | 7145 | 7137 | 21375 |
| Race/Ethnicity, Customized(Participants) | Rivaroxaban 2.5mg + Aspirin 100mg | Rivaroxaban 5mg + Aspirin Placebo | Rivaroxaban Placebo + Aspirin 100mg | Total |
|---|---|---|---|---|
| Chinese | 388 | 381 | 376 | 1145 |
| Hispanic | 1769 | 1751 | 1758 | 5278 |
| White/Caucasian | 5673 | 5672 | 5682 | 17027 |
| South Asian | 107 | 102 | 106 | 315 |
| Other Asian | 956 | 938 | 915 | 2809 |
| Black/African American | 76 | 94 | 92 | 262 |
| Other | 183 | 179 | 197 | 559 |
Showing the first 100 of 565 sites across 33 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.clinicalstudydatarequest.com to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the Study sponsors section of the portal.
Ran from Feb 2013 to primary completion in Jul 2017, 52 months.
Results were first posted in Oct 2018, 1 year 2 months after primary completion.
Of 29 industry-sponsored phase 3 interventional studies under Coronary Artery Disease, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 55. This study's 52 months is close to that.
Counting every sponsor, half of 61 studies reached it within 47 months; a quarter within 20 and three quarters within 58.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Rivaroxaban · Aspirin